Full-Time

Manager – Accounting

Confirmed live in the last 24 hours

Freenome

Freenome

201-500 employees

Develops blood tests for early cancer detection

Compensation Overview

$131.3k - $201k/yr

+ Pre-IPO Equity + Cash Bonuses

Senior

Daly City, CA, USA

This is a hybrid role based in our Brisbane, California headquarters.

Category
Financial Accounting
Management Accounting
Accounting
Required Skills
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in accounting, CPA preferred
  • 6+ years of accounting experience, preferably in biotechnology or pharmaceuticals industry
  • Superior analytical and modeling skills including advanced proficiency in Excel and the ability to quickly manipulate and analyze large data sets and build reports
  • Strong work ethic including sound judgement, outstanding interpersonal skills and ability to work independently
  • Ability to drive projects and tasks to timely review and completion
Responsibilities
  • Monthly & quarterly close general ledger reconciliations for accounts such as Fixed Assets, Expense accruals and clinical trial accruals
  • Prepare, maintain and update standard operating procedures and internal controls for assigned areas to establish compliance related to Sarbanes-Oxley (SOX) 404
  • Prepare monthly and quarterly flux analysis and financial reporting
  • Support interim and year end audit preparations, explanations and documentation
  • Prepare tax related support for filings such as Property Tax, Sales and Use Tax as well as government surveys
  • Identify and drive areas of process improvement to reduce the accounting close process, enhance existing procedures, controls and streamline operations
  • Assist in various system Implementations in preparation of commercialization
  • Ad-hoc projects as the company continues to grow
Desired Qualifications
  • Public accounting experience a plus
  • Experience with Netsuite is a plus
  • Experience with coaching and mentoring staff
  • Capacity to handle a high volume of transactions in a fast-paced environment
  • Results and goal-oriented mindset with an opportunistic eye towards process improvements
  • Ability to prioritize and organize work effectively, with exceptional cross-functional collaboration and communication skills

Freenome focuses on improving cancer detection through advanced blood tests. The company uses a multiomics approach, analyzing various biological data types, including genomics and proteomics, to find cancer markers in the blood. Its primary clients are healthcare providers and research institutions, and it generates revenue by selling these non-invasive diagnostic tests. Freenome is also involved in clinical trials and research collaborations. With significant funding, including a recent $270 million investment, the company aims to enhance its colorectal cancer blood test and expand its clinical trials. Freenome's goal is to lead in cancer diagnostics by providing early detection solutions while fostering a collaborative and inclusive workplace.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$1.1B

Headquarters

San Francisco, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent $254 million funding boosts Freenome's clinical programs and platform capabilities.
  • Partnership with Walgreens enhances clinical trial diversity and robustness.
  • Acquisition of Oncimmune strengthens Freenome's immunodiagnostics and multiomics platform.

What critics are saying

  • Leadership change with new CEO Aaron Elliott may lead to strategic shifts.
  • Layoffs of 100 employees could impact morale and productivity.
  • Dependence on large-scale clinical trials poses risks if results are unfavorable.

What makes Freenome unique

  • Freenome uses a unique multiomics approach for early cancer detection.
  • The company focuses on non-invasive blood tests for proactive disease management.
  • Freenome's platform designs personalized health conditions based on cell-free genome analysis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive market-based salaries

Annual bonus opportunities

Relocation packages

Medical, dental, & vision coverage

401k

Wellness programs

Equity

PTO

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

4%
PR Newswire
Apr 14th, 2025
Freenome Names Aaron Elliott, Ph.D., As Chief Executive Officer To Lead The Company'S Next Chapter Of Commercial Growth And Product Innovation

Accomplished industry leader brings specialized experience to advance Freenome's screening blood tests for colorectal cancer, lung cancer and additional indications BRISBANE, Calif., April 8, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron Elliott, Ph.D., as its new chief executive officer. With nearly 20 years in the diagnostics industry, Aaron has provided leadership at the intersection of RD, product development and commercialization to drive market traction and expand clinical impact. His experience includes a deep focus on early cancer detection and multiomics that aligns with Freenome's mission to make cancer screening accessible for everyone

SDBN
Apr 24th, 2024
Cancer testing company Freenome to lay off 100 employees

Cancer testing company Freenome to lay off 100 employees.

GlobalData
Apr 14th, 2024
Freenome swings $254m investment

The announcement comes alongside two ongoing clinical trials launched by Freenome, including its prospective PREEMPT CRC study (NCT04369053), a longitudinal real-world data study consisting of under 40,000 participants evaluating the company's blood-based screening test among adults at average risk for CRC.

Freenome
Feb 16th, 2024
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection | Freenome

Roche led the financing alongside existing and new investors. The funds will progress clinical programs and expand platform capabilities.

PR Newswire
Dec 12th, 2023
Freenome Initiates Proact Lung Clinical Study For The Early Detection Of Lung Cancer Using Blood Test Developed On Multiomics Platform

– Registrational study targets enrollment of 20,000 individuals at high risk of lung cancer –SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 /PRNewswire/ -- Freenome, a privately held company developing multiomics blood tests for early cancer detection, today announced the initiation of its PROACT LUNG study and provided an update on its lung cancer research, including the ongoing Vallania study. The study is intended to validate the clinical performance of the Freenome blood test for lung cancer screening. The test combines lung cancer-specific biomarkers with cancer-common markers identified on Freenome's proprietary multiomics platform. This is Freenome's second blood-based test developed on the platform and being evaluated in a prospective clinical study.Early detection of lung cancer, while in its most treatable stage, leads to better clinical outcomes for patients.1,2 Recently, the United States Preventive Services Task Force expanded the recommended ages and smoking history for lung cancer screenings, reaffirming the importance of early detection. In people at high risk for lung cancer, annual screening with a low-dose CT (LDCT) scan is typically recommended as part of the standard of care (SOC)